Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
0.01 AUD 0.00(0%)
Last update at 2026-11-11T05:10:00Z
VOLUME
32838
Market Cap
12.69M

Momentum Score

…

TrivarX Limited, a biotechnology company, engages in the development of AI-driven, and scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. It is also involved in research, development, and commercialisation of diagnostic and pharmaceutical products. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is based in Hawthorn East, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Trivarx Ltd (ASX:TRI) is limited, with few readily available disclosures or analyst coverage that makes its core business and strategy unclear. Until the company publishes clearer operational and financial information, investors may benefit from monitoring filings and announcements to assess any potential growth drivers or strategic initiatives.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
-
Gross Profit TTM
0.01M
Debt / Equity
0.01
ROE
-61.23%
Net Debt
-2.32M
ROCE
-52.44%
Diluted EPS TTM
-0.96

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -8.76M -1.97M -1.24M -3.12M -12.72M
Net income -8.76M -0.94M -1.24M -3.12M -12.72M
Selling general administrative - 0.97M 1.07M 0.75M 1.41M
Selling and marketing expenses - - 0.05M 0.08M 0.02M
Gross profit -6.47M -0.05M 0.89M 0.02M 0.04M
Reconciled depreciation - - 0.09M 0.54M 0.45M
Ebit -8.42M -1.94M -1.22M -1.79M -2.67M
Ebitda -1.95M -1.89M -1.13M -1.25M -2.22M
Depreciation and amortization 6.47M 0.05M 0.09M 0.54M 0.45M
Operating income -8.42M -2.04M -1.42M -1.79M -2.67M
Other operating expenses 8.42M 2.04M 2.31M 2.75M 3.68M
Interest expense 0.01M 0.03M 0.01M 0.01M 0.01M
Tax provision - - 0.00M 0.00M 0.00M
Interest income - 0.01M 0.00M 0.01M 0.01M
Net interest income - - -0.01M -0.01M -0.01M
Income tax expense - -1.03M - 0.95M 0.01M
Total revenue - 1.13M 0.89M 0.02M 0.04M
Total operating expenses 1.95M 1.99M 2.31M 2.75M 3.68M
Cost of revenue 6.47M 0.05M 0.00M 0.00M 0.00M
Total other income expense net -0.34M 0.06M -1.24M -0.38M -10.05M
Net income from continuing ops - - -1.43M -3.12M -12.72M
Net income applicable to common shares - -0.94M -1.43M -3.12M -12.72M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 16.53M 13.48M 11.07M 8.06M 8.49M
Intangible assets - 12.01M 10.13M 7.63M 7.21M
Other current assets 0.05M 0.05M 0.07M 0.09M 0.17M
Total liab 0.57M 0.83M 1.17M 1.76M 1.38M
Total stockholder equity 15.97M 12.65M 9.89M 6.30M 7.11M
Deferred long term liab - - - 2.47M 2.01M
Other current liab 0.12M - 0.16M 0.13M 0.31M
Common stock 113.73M 109.96M - 101.80M 99.45M
Capital stock - - 106.58M 101.80M 99.45M
Retained earnings -112.67M -97.31M -102.97M -101.71M -98.59M
Other assets - 0.01M - 0.02M 2.02M
Cash 2.44M 1.25M 0.85M 0.21M 1.03M
Total current liabilities 0.47M 0.70M 1.17M 1.76M 1.38M
Current deferred revenue - - - 0.14M -
Net debt -2.32M - - -0.11M -0.97M
Short term debt 0.04M 0.00M - 0.10M 0.07M
Short long term debt total 0.13M - - 0.10M 0.07M
Other stockholder equity - - - 6.20M 6.24M
Property plant equipment - 0.16M - 0.11M 0.07M
Total current assets 2.49M 1.30M 0.92M 0.30M 1.20M
Net tangible assets - - - 1.18M 1.90M
Accounts payable 0.32M - 0.94M 1.38M 1.00M
Accumulated other comprehensive income 14.92M - - 6.20M 6.24M
Non currrent assets other 0.00M - 0.01M 0.02M 0.01M
Non current assets total 14.04M - 10.15M 7.75M 7.29M
Capital lease obligations - - 0.02M 0.10M 0.07M
Long term debt total - 0.13M - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - -2.50M -2.26M -3.11M
Change to liabilities - - - 0.26M 0.39M
Total cashflows from investing activities -1.17M -2.09M -2.85M -2.26M -3.11M
Net borrowings - - -0.01M -0.04M -0.04M
Total cash from financing activities 3.87M 2.68M 4.32M 2.47M 3.33M
Change to operating activities - - - -0.03M 0.26M
Net income -8.76M -0.94M -1.43M -3.12M -12.72M
Change in cash 1.20M 0.40M 0.63M -0.82M -1.28M
Begin period cash flow 1.25M 0.85M 0.21M 1.03M 2.31M
End period cash flow 2.44M 1.25M 0.85M 0.21M 1.03M
Total cash from operating activities -1.51M -0.19M -1.48M -0.93M -12.28M
Issuance of capital stock - - 4.70M 2.51M 3.38M
Depreciation 6.47M 0.05M - 0.10M 0.45M
Other cashflows from investing activities - - - 0.00M 0.00M
Change to account receivables - - - - 0.02M
Sale purchase of stock - 2.73M 4.70M 2.51M 3.38M
Other cashflows from financing activities -0.05M -0.06M -0.12M -0.04M -0.04M
Change to netincome - - - 1.36M 10.61M
Capital expenditures 1.51M 2.09M 2.85M 2.26M 3.11M
Change in working capital - 0.47M 0.89M 0.94M 0.97M
Other non cash items 0.78M 0.23M - - 12.28M
Free cash flow - -0.19M -3.70M -3.19M -15.39M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TRI
Trivarx Ltd
-
-%
0.01 - 5.58 871.25 0.80 79.57 -0.32
PME
Pro Medicus Ltd
-4.52
2.18%
202.79 81.98 106.38 83.13 43.70 74.38 95.34
4DX
4DMEDICAL Ltd
-0.06
2.53%
2.31 - - 205.57 8.53 170.03 -7.29
CGS
Cogstate Ltd
0.12
3.30%
3.76 33.80 27.86 9.59 6.95 6.35 19.27
AYA
ARTRYA Ltd
-0.14
3.91%
3.44 - - 20505.14 7.00 16927.51 0.33

Profile*

Trivarx Ltd

TrivarX Limited, a biotechnology company, engages in the development of AI-driven, and scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. It is also involved in research, development, and commercialisation of diagnostic and pharmaceutical products. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is based in Hawthorn East, Australia.

Suite 1.01, Hawthorn East, VIC, Australia, 3123

61 3 8319 0962

Name Title Year Born
Dr. Thomas R. Young M.D. Chief Exec. Officer NA
Ms. Renee Stanton-Horne Operations & Account Mang. NA
Ms. Stephanie Ottens Investor Relations Director NA
Mr. Josh Purdy PR Director NA
Dr. Michael Player Head of Research NA
Dr. Matthew Flax Head of Algorithm Devel. Team NA
Mr. Archie Defillo M.D. Chief Medical Officer NA
Ms. Jennifer Solitario Sr. VP of Corp. Health NA
Mr. Massimiliano Grassi Head of Artificial Intelligence NA
Mr. Mathew Watkins C.A. Company Sec. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…